HLA class II polymorphism in Latin American patients with multiple sclerosis

Olga Lucía Rojas, Adriana Rojas-Villarraga, Paola Cruz-Tapias, Jorge Luis Sánchez, Juan Camilo Suárez-Escudero, Manuel Alfonso Patarroyo, Juan Manuel Anaya

Resultado de la investigación: Contribución a RevistaRevisión Literaria

23 Citas (Scopus)

Resumen

Objective: To identify HLA-DRB1 alleles contributing to susceptibility to multiple sclerosis (MS) in a Colombian population and to estimate the common effect size of HLA class II on MS susceptibility in Latin American populations through a meta-analysis. Methods: A total of 65 Colombian patients with MS and 184 matched controls were included. HLA-DRB1 typing was done using the sequence-specific oligonucleotide probe method. A bivariate and a multivariate logistic regression analyses were done. Case-control studies performed in Latin America were searched up to January 2009 through a systematic review of the literature. Effect summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by means of the random effect model. Results: A total of 464 cases and 2581 controls from 7 studies and the results of the present study in Colombians were analyzed. HLA-DRB1*15 (OR: 2.3; 95% CI: 1.68-3.07; p <0.001) and HLA-DQB1*06 (OR: 2.2; 95% CI: 1.54-3.07; p <0.001) groups as well as DRB1*1501 (OR: 2.6; 95% CI: 1.67-4.02; p <0.001), DRB1*1503 (OR: 2.2; 95% CI: 1.39-3.62; p = 0.001) and DQB1*0602 (OR: 2.5; 95% CI: 1.66-3.71; p <0.001) alleles were found to be risk factors for MS. The myelin basic protein immunodominant sequence 221VHFFKNIVT229 was predicted to strongly and simultaneously bind to HLA-DRB1*1501 and *1503. Conclusion: The current study highlights the effect size of HLA class II in MS in Latin America and confirms similar allelic risk factors across diverse populations. Receptor-ligand interactions in the HLA-antigenic peptide complex could have potential predictive and therapeutical implications. © 2009 Elsevier B.V. All rights reserved.
Idioma originalEnglish (US)
Páginas (desde-hasta)407-413
Número de páginas7
PublicaciónAutoimmunity Reviews
DOI
EstadoPublished - abr 1 2010

Huella dactilar

Multiple Sclerosis
HLA-DRB1 Chains
Odds Ratio
Confidence Intervals
Latin America
Alleles
Population
Histocompatibility Testing
Myelin Basic Protein
Oligonucleotide Probes
Meta-Analysis
Case-Control Studies
Logistic Models
Regression Analysis
Ligands
Peptides
HLA-DQB1 antigen

Citar esto

Rojas, O. L., Rojas-Villarraga, A., Cruz-Tapias, P., Sánchez, J. L., Suárez-Escudero, J. C., Patarroyo, M. A., & Anaya, J. M. (2010). HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmunity Reviews, 407-413. https://doi.org/10.1016/j.autrev.2009.11.001
Rojas, Olga Lucía ; Rojas-Villarraga, Adriana ; Cruz-Tapias, Paola ; Sánchez, Jorge Luis ; Suárez-Escudero, Juan Camilo ; Patarroyo, Manuel Alfonso ; Anaya, Juan Manuel. / HLA class II polymorphism in Latin American patients with multiple sclerosis. En: Autoimmunity Reviews. 2010 ; pp. 407-413.
@article{6088cc07b4db4014a46f0a0f22af0fc1,
title = "HLA class II polymorphism in Latin American patients with multiple sclerosis",
abstract = "Objective: To identify HLA-DRB1 alleles contributing to susceptibility to multiple sclerosis (MS) in a Colombian population and to estimate the common effect size of HLA class II on MS susceptibility in Latin American populations through a meta-analysis. Methods: A total of 65 Colombian patients with MS and 184 matched controls were included. HLA-DRB1 typing was done using the sequence-specific oligonucleotide probe method. A bivariate and a multivariate logistic regression analyses were done. Case-control studies performed in Latin America were searched up to January 2009 through a systematic review of the literature. Effect summary odds ratios (ORs) and 95{\%} confidence intervals (CIs) were obtained by means of the random effect model. Results: A total of 464 cases and 2581 controls from 7 studies and the results of the present study in Colombians were analyzed. HLA-DRB1*15 (OR: 2.3; 95{\%} CI: 1.68-3.07; p <0.001) and HLA-DQB1*06 (OR: 2.2; 95{\%} CI: 1.54-3.07; p <0.001) groups as well as DRB1*1501 (OR: 2.6; 95{\%} CI: 1.67-4.02; p <0.001), DRB1*1503 (OR: 2.2; 95{\%} CI: 1.39-3.62; p = 0.001) and DQB1*0602 (OR: 2.5; 95{\%} CI: 1.66-3.71; p <0.001) alleles were found to be risk factors for MS. The myelin basic protein immunodominant sequence 221VHFFKNIVT229 was predicted to strongly and simultaneously bind to HLA-DRB1*1501 and *1503. Conclusion: The current study highlights the effect size of HLA class II in MS in Latin America and confirms similar allelic risk factors across diverse populations. Receptor-ligand interactions in the HLA-antigenic peptide complex could have potential predictive and therapeutical implications. {\circledC} 2009 Elsevier B.V. All rights reserved.",
author = "Rojas, {Olga Luc{\'i}a} and Adriana Rojas-Villarraga and Paola Cruz-Tapias and S{\'a}nchez, {Jorge Luis} and Su{\'a}rez-Escudero, {Juan Camilo} and Patarroyo, {Manuel Alfonso} and Anaya, {Juan Manuel}",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.autrev.2009.11.001",
language = "English (US)",
pages = "407--413",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

Rojas, OL, Rojas-Villarraga, A, Cruz-Tapias, P, Sánchez, JL, Suárez-Escudero, JC, Patarroyo, MA & Anaya, JM 2010, 'HLA class II polymorphism in Latin American patients with multiple sclerosis', Autoimmunity Reviews, pp. 407-413. https://doi.org/10.1016/j.autrev.2009.11.001

HLA class II polymorphism in Latin American patients with multiple sclerosis. / Rojas, Olga Lucía; Rojas-Villarraga, Adriana; Cruz-Tapias, Paola; Sánchez, Jorge Luis; Suárez-Escudero, Juan Camilo; Patarroyo, Manuel Alfonso; Anaya, Juan Manuel.

En: Autoimmunity Reviews, 01.04.2010, p. 407-413.

Resultado de la investigación: Contribución a RevistaRevisión Literaria

TY - JOUR

T1 - HLA class II polymorphism in Latin American patients with multiple sclerosis

AU - Rojas, Olga Lucía

AU - Rojas-Villarraga, Adriana

AU - Cruz-Tapias, Paola

AU - Sánchez, Jorge Luis

AU - Suárez-Escudero, Juan Camilo

AU - Patarroyo, Manuel Alfonso

AU - Anaya, Juan Manuel

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Objective: To identify HLA-DRB1 alleles contributing to susceptibility to multiple sclerosis (MS) in a Colombian population and to estimate the common effect size of HLA class II on MS susceptibility in Latin American populations through a meta-analysis. Methods: A total of 65 Colombian patients with MS and 184 matched controls were included. HLA-DRB1 typing was done using the sequence-specific oligonucleotide probe method. A bivariate and a multivariate logistic regression analyses were done. Case-control studies performed in Latin America were searched up to January 2009 through a systematic review of the literature. Effect summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by means of the random effect model. Results: A total of 464 cases and 2581 controls from 7 studies and the results of the present study in Colombians were analyzed. HLA-DRB1*15 (OR: 2.3; 95% CI: 1.68-3.07; p <0.001) and HLA-DQB1*06 (OR: 2.2; 95% CI: 1.54-3.07; p <0.001) groups as well as DRB1*1501 (OR: 2.6; 95% CI: 1.67-4.02; p <0.001), DRB1*1503 (OR: 2.2; 95% CI: 1.39-3.62; p = 0.001) and DQB1*0602 (OR: 2.5; 95% CI: 1.66-3.71; p <0.001) alleles were found to be risk factors for MS. The myelin basic protein immunodominant sequence 221VHFFKNIVT229 was predicted to strongly and simultaneously bind to HLA-DRB1*1501 and *1503. Conclusion: The current study highlights the effect size of HLA class II in MS in Latin America and confirms similar allelic risk factors across diverse populations. Receptor-ligand interactions in the HLA-antigenic peptide complex could have potential predictive and therapeutical implications. © 2009 Elsevier B.V. All rights reserved.

AB - Objective: To identify HLA-DRB1 alleles contributing to susceptibility to multiple sclerosis (MS) in a Colombian population and to estimate the common effect size of HLA class II on MS susceptibility in Latin American populations through a meta-analysis. Methods: A total of 65 Colombian patients with MS and 184 matched controls were included. HLA-DRB1 typing was done using the sequence-specific oligonucleotide probe method. A bivariate and a multivariate logistic regression analyses were done. Case-control studies performed in Latin America were searched up to January 2009 through a systematic review of the literature. Effect summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by means of the random effect model. Results: A total of 464 cases and 2581 controls from 7 studies and the results of the present study in Colombians were analyzed. HLA-DRB1*15 (OR: 2.3; 95% CI: 1.68-3.07; p <0.001) and HLA-DQB1*06 (OR: 2.2; 95% CI: 1.54-3.07; p <0.001) groups as well as DRB1*1501 (OR: 2.6; 95% CI: 1.67-4.02; p <0.001), DRB1*1503 (OR: 2.2; 95% CI: 1.39-3.62; p = 0.001) and DQB1*0602 (OR: 2.5; 95% CI: 1.66-3.71; p <0.001) alleles were found to be risk factors for MS. The myelin basic protein immunodominant sequence 221VHFFKNIVT229 was predicted to strongly and simultaneously bind to HLA-DRB1*1501 and *1503. Conclusion: The current study highlights the effect size of HLA class II in MS in Latin America and confirms similar allelic risk factors across diverse populations. Receptor-ligand interactions in the HLA-antigenic peptide complex could have potential predictive and therapeutical implications. © 2009 Elsevier B.V. All rights reserved.

U2 - 10.1016/j.autrev.2009.11.001

DO - 10.1016/j.autrev.2009.11.001

M3 - Literature review

SP - 407

EP - 413

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -

Rojas OL, Rojas-Villarraga A, Cruz-Tapias P, Sánchez JL, Suárez-Escudero JC, Patarroyo MA y otros. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmunity Reviews. 2010 abr 1;407-413. https://doi.org/10.1016/j.autrev.2009.11.001